Zobrazeno 61 - 70
of 5 689
pro vyhledávání: ''
Autor:
Sasithorn Foyhirun, Artit Jinawath, N. Trachu, Suda Sanpapant, Lalida Arsa, Teerada Siripoon, Duangjai Pangpunyakulchai, Nuttapong Ngamphaiboon, Natini Jinawath, P. Pattaranutaporn
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
BMC Cancer
BMC Cancer
Background Lower prevalence HPV infection has been previously reported in Thai population when compared with Western countries. p16 expression indicates HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), but not non-OPSCC. We therefore eva
Autor:
Hironaga Satake, Nobuhiro Shibata, Mototsugu Shimokawa, T. Ikoma, Hiroki Nagai, Shogen Boku, Hisateru Yasui, Toshihiko Matsumoto, Masahito Kotaka
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background RAS/BRAFV600E mutations are the most remarkable oncogenic driver mutations in colorectal cancer (CRC) and play an important role in treatment selection. No data are available regarding the clinical and prognostic features of patients with
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background Excess body fatness, commonly approximated by a one-off determination of body mass index (BMI), is associated with increased risk of at least 13 cancers. Modelling of longitudinal BMI data may be more informative for incident cancer associ
Autor:
Zhenrong Tang, Yuran Dai, Shengchun Liu, Ailin Lan, Rui Chen, Yu Wang, Yang Peng, Linshan Jiang, Nan Ding, Yudi Jin, Yihua Wang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
BMC Cancer
BMC Cancer
Background The aim of this study was to evaluate the relationship between pre-treatment plasma fibrinogen (Fib) level and pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer patients and to assess the role of plasm
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of sequential therapy with sorafeni
Autor:
Andrew Hickey, Anne McMaster, Yoo Young Dominique Lee, Esben S. Worm, Doan Trang Nguyen, Trevor Moodie, Per Rugaard Poulsen, Paul J. Keall, Julie Chu, Nicole Pritchard, Nicholas Hardcastle, Britta Weber, Jeremy T. Booth, Tim Wang, David Pryor, Elizaveta Mitkina Tabaksblat, Ricky O'Brien, Val Gebski
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer
Lee, Y Y D, Nguyen, D T, Moodie, T, O’Brien, R, McMaster, A, Hickey, A, Pritchard, N, Poulsen, P, Tabaksblat, E M, Weber, B, Worm, E, Pryor, D, Chu, J, Hardcastle, N, Booth, J, Gebski, V, Wang, T & Keall, P 2021, ' Study protocol of the LARK (TROG 17.03) clinical trial : a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring ', BMC Cancer, vol. 21, no. 1, 494 . https://doi.org/10.1186/s12885-021-08184-x
BMC Cancer
Lee, Y Y D, Nguyen, D T, Moodie, T, O’Brien, R, McMaster, A, Hickey, A, Pritchard, N, Poulsen, P, Tabaksblat, E M, Weber, B, Worm, E, Pryor, D, Chu, J, Hardcastle, N, Booth, J, Gebski, V, Wang, T & Keall, P 2021, ' Study protocol of the LARK (TROG 17.03) clinical trial : a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring ', BMC Cancer, vol. 21, no. 1, 494 . https://doi.org/10.1186/s12885-021-08184-x
Background Stereotactic Ablative Body Radiotherapy (SABR) is a non-invasive treatment which allows delivery of an ablative radiation dose with high accuracy and precision. SABR is an established treatment for both primary and secondary liver malignan
Autor:
Jingyu Chen, Dongyu Bai, Pan Yin, Ji Zhang, Dong Liu, Yongxiang Su, Xiuyi Yu, Bingqing Yue, Guang Zhao, Chutong Huang, Jie Jiang, Guojun Geng
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background A pathologically confirmed negative margin is required when performing sublobar resection in patients with early stage peripheral lung adenocarcinoma. However, the optimal margin distance to ensure complete tumor resection while preserving
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer
BMC Cancer
Background Cancer survivors who develop breast cancer as a second malignancy (BCa-2) are common. Yet, little is known about the prognosis of BCa-2 compared to first primary breast cancer (BCa-1). Methods Using the Surveillance, Epidemiology, and End
Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer
BMC Cancer
Background Malignant tumor is one of the most serious diseases endangering human health. Circular RNAs play an important role in the tumorigenesis and progression of various malignant tumors. Although various studies have investigated the biological
Autor:
Yunfan Luo, Wei Liu, Ze-Hong Lv, Junzheng Li, Bolong Yu, Juan Lu, Xiaofei Yuan, Yanfei Li, Xiong Liu, Xiaohong Peng, Xinyu Peng, Bijun Liang, Shuting Wu
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer
BMC Cancer
Background Although the National Comprehensive Cancer Network (NCCN) Guidelines recommend CCRT+AC and IC + CCRT as level 2A evidence for treatment of the locoregionally advanced NPC (II-IVa), IC + CCRT+AC could also be an alternative but it is seldom